Showing 41-50 of 747 results for "".
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Cellulite Reduction Seen With Cellfina Lasts Five Yearshttps://practicaldermatology.com/news/cellulite-reduction-seen-with-cellfina-lasts-five-years/2457566/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. This new data b
- New Applicator Suggests Cryolipolysis May Be an Option for Male Pseudogynecomastiahttps://practicaldermatology.com/news/new-applicator-suggests-cryolipolysis-may-be-an-option-for-male-pseudogynecomastia/2457678/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent study in Lasers in Surgery and Medicine (LSM). “This split-b
- Lancer Skincare Launches At-Home Producthttps://practicaldermatology.com/news/20130117-lancer_skincare_launches_at-home_product/2459635/The Lancer Skincare collection now includes the Microcurrent Powerboost, a hand-held device to help tone, tighten, and correct imbalances in the skin. According to the company, the Microcurrent Powerboost allows daily skincare products to b
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- LEO Pharma Acquires Worldwide Rights to Dersimelagon for EPP, XLPhttps://practicaldermatology.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-epp-xlp/2488131/LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma, adding a late-stage investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to its rare dermatology pipeline. Under the agreement, LEO Pharma w
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w